-
1 Comment
Pieris Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 34.2% above its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.1.
Pieris Pharmaceuticals, Inc's total revenue sank by 89.1% to $2M since the same quarter in the previous year.
Its net income has dropped by 1767.7% to $-14M since the same quarter in the previous year.
Finally, its free cash flow grew by 7.6% to $-14M since the same quarter in the previous year.
Based on the above factors, Pieris Pharmaceuticals, Inc gets an overall score of 3/5.
| CurrencyCode | USD |
|---|---|
| Industry | Biotechnology |
| Sector | Healthcare |
| ISIN | US7207951036 |
| Exchange | NASDAQ |
| PE Ratio | None |
|---|---|
| Dividend Yield | 0.0% |
| Beta | 1.17 |
| Market Cap | 56M |
| Target Price | 7 |
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin based drug candidate, elarekibep used for the treatment of asthma; and PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis. The company also develops PRS-344/S09501 2that consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for PIRS using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
